Taking in consideration these results and the high pathologic response rate which is reported in the literature for the TN BC subgroup, we believe that early 18F-FDG-PET/CT assessment during PCT should be addressed to a more chemoresistant subtype of disease, where therapeutic options to cytotoxic treatment can be available.
展开▼